NASDAQ:FATE Fate Therapeutics (FATE) Stock Price, News & Analysis $2.53 +0.01 (+0.40%) Closing price 09/18/2026 04:00 PM EasternExtended Trading$2.59 +0.06 (+2.21%) As of 09/18/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Fate Therapeutics Stock (NASDAQ:FATE) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Fate Therapeutics alerts:Sign Up Key Stats Today's Range$2.47▼$2.6150-Day Range$2.31▼$3.0252-Week Range$0.94▼$3.23Volume4.19 million shsAverage Volume1.24 million shsMarket Capitalization$303.14 millionP/E RatioN/ADividend YieldN/APrice Target$5.90Consensus RatingHold Company Overview Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing cellular immunotherapies for cancer and autoimmune diseases. The company uses its induced pluripotent stem cell (iPSC) platform to produce potentially off-the-shelf immune-cell therapies designed to be manufactured at scale and administered to multiple patients. Its research and development programs include iPSC-derived natural killer (NK) cell and T-cell therapies. Notable candidates have included FT596, an iPSC-derived NK-cell therapy, and FT819, an iPSC-derived T-cell therapy targeting CD19. Fate has evaluated its investigational therapies in clinical studies for hematologic malignancies and has pursued additional applications in solid tumors and autoimmune disorders. The company does not have commercially approved products. Founded in 2007 and headquartered in San Diego, California, Fate Therapeutics conducts its research and clinical development activities primarily in the United States, with clinical studies potentially involving sites in other regions. Scott Wolchko serves as the company's president and chief executive officer.AI Generated. May Contain Errors. Read More Fate Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks55th Percentile Overall ScoreFATE MarketRank™: Fate Therapeutics scored higher than 55% of companies evaluated by MarketBeat, and ranked 404th out of 897 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.0 / 5Analyst RatingHold Consensus RatingFate Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.38, and is based on no strong buy ratings, 4 buy ratings, 3 hold ratings, and 1 sell rating.Upside PotentialFate Therapeutics has a consensus price target of $5.90, representing about 133.2% upside from its current price of $2.53.Amount of Analyst CoverageFate Therapeutics has only been the subject of 4 research reports in the past 90 days.Read more about Fate Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Fate Therapeutics are expected to grow in the coming year, from ($1.03) to ($1.01) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Fate Therapeutics is -2.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Fate Therapeutics is -2.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioFate Therapeutics has a P/B Ratio of 1.41. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Fate Therapeutics' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted7.98% of the float of Fate Therapeutics has been sold short.Short Interest Ratio / Days to CoverFate Therapeutics has a short interest ratio ("days to cover") of 6.23.Change versus previous monthShort interest in Fate Therapeutics has recently increased by 7.09%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldFate Therapeutics does not currently pay a dividend.Dividend GrowthFate Therapeutics does not have a long track record of dividend growth. News and Social Media3.5 / 5News Sentiment0.66 News SentimentFate Therapeutics has a news sentiment score of 0.66. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.56 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Fate Therapeutics this week, compared to 3 articles on an average week.Search InterestOnly 2 people have searched for FATE on MarketBeat in the last 30 days. This is a decrease of -86% compared to the previous 30 days.MarketBeat Follows2 people have added Fate Therapeutics to their MarketBeat watchlist in the last 30 days. Company Ownership0.9 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Fate Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders4.74% of the stock of Fate Therapeutics is held by insiders.Percentage Held by Institutions97.54% of the stock of Fate Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Fate Therapeutics' insider trading history. Receive FATE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Fate Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. FATE Stock News HeadlinesFate Therapeutics To Present Off-The-Shelf CAR T Portfolio At ACR Convergence 2026September 16, 2026 | rttnews.comFate Therapeutics Announces Four ACR Convergence 2026 Abstracts Highlighting Off-the-Shelf CAR T-Cell Programs in Autoimmune DiseaseSeptember 16, 2026 | quiverquant.comQHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - but now he believes he's found something better. This under-the-radar company sits at the intersection of America's two most important industries, including AI, pays massive dividends, and attracted a famous money manager who put 60% of his multi-billion-dollar fund into it. Tilson is revealing the name and ticker symbol completely free - no credit card or email required. | Stansberry Research (Ad)Fate Therapeutics Selected for Four Presentations Highlighting its Off-the-Shelf CAR T-Cell Portfolio in Autoimmune Disease at ACR Convergence 2026September 16, 2026 | globenewswire.comFate Therapeutics, Inc. (NASDAQ:FATE) Given Consensus Recommendation of "Hold" by AnalystsSeptember 14, 2026 | americanbankingnews.comFate Therapeutics, Inc.: Fate Therapeutics Announces Encore Clinical Data Presentation of FT819 Off-the-Shelf CAR T-Cell Product Candidate at the CCR - West 2026 MeetingSeptember 9, 2026 | finanznachrichten.deFate Therapeutics to Present FT819 and FT839 Data at CCR West Meeting, Highlighting Safety and Efficacy in Autoimmune DiseaseSeptember 9, 2026 | quiverquant.comQFate Therapeutics Announces Encore Clinical Data Presentation of FT819 Off-the-Shelf CAR T-Cell Product Candidate at the CCR – West 2026 MeetingSeptember 9, 2026 | globenewswire.comSee More Headlines FATE Stock Analysis - Frequently Asked Questions How have FATE shares performed this year? Fate Therapeutics' stock was trading at $0.9826 at the start of the year. Since then, FATE shares have increased by 157.5% and is now trading at $2.53. How were Fate Therapeutics' earnings last quarter? Fate Therapeutics, Inc. (NASDAQ:FATE) announced its quarterly earnings data on Thursday, August, 13th. The biopharmaceutical company reported ($0.25) earnings per share for the quarter, topping the consensus estimate of ($0.25) by $0.00. The biopharmaceutical company earned $2.08 million during the quarter, compared to analyst estimates of $1.94 million. Fate Therapeutics had a negative trailing twelve-month return on equity of 65.08% and a negative net margin of 1,941.09%. When did Fate Therapeutics IPO? Fate Therapeutics (FATE) raised $47 million in an initial public offering on Tuesday, October 1st 2013. The company issued 6,666,667 shares at $6.00-$8.00 per share. Who are Fate Therapeutics' major shareholders? Fate Therapeutics' top institutional shareholders include BlackRock Inc. (6.26%), Johnson & Johnson (2.90%), Connor Clark & Lunn Investment Management Ltd. (0.49%) and Ieq Capital LLC (0.42%). Insiders that own company stock include Redmile Group, Llc, Cindy Tahl, J Scott Wolchko, Bahram Valamehr, Jerome Charles Bressi, Edward J Dulac III and Yuan Xu. View institutional ownership trends. How do I buy shares of Fate Therapeutics? Shares of FATE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Fate Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Fate Therapeutics investors own include NVIDIA (NVDA), Tesla (TSLA), Advanced Micro Devices (AMD), Meta Platforms (META), Alibaba Group (BABA) and Netflix (NFLX). Company Calendar Last Earnings8/13/2026Today9/19/2026Next Earnings (Estimated)10/29/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (12m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 FATE's financial health is in the Green zone, according to TradeSmith. FATE has been in this zone for over 12 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:FATE CIK1434316 Webwww.fatetherapeutics.com Phone(858) 875-1800FaxN/AEmployees161Year Founded2007Price Target and Rating Average Price Target for Fate Therapeutics$5.90 High Price Target$8.00 Low Price Target$3.50 Potential Upside/Downside+133.2%Consensus RatingHold Rating Score (0-4)2.38 Research Coverage8 Analysts Profitability EPS (Trailing Twelve Months)($1.05) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$136.32 million Net Margins-1,941.09% Pretax Margin-1,941.09% Return on Equity-65.08% Return on Assets-41.73% Debt Debt-to-Equity RatioN/A Current Ratio4.85 Quick Ratio4.85 Sales & Book Value Annual Sales$6.65 million Price / Sales45.59 Cash FlowN/A Price / Cash FlowN/A Book Value$1.80 per share Price / Book1.41Miscellaneous Outstanding Shares119,820,000Free Float114,141,000Market Cap$303.14 million OptionableOptionable Beta2.54 Social Links The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free Report This page (NASDAQ:FATE) was last updated on 9/20/2026 by MarketBeat.com Staff. From Our Partners$40,000,000,000,000The national debt just hit 40 trillion dollars, and the U.S. now spends more on interest payments than on its ...American Alternative | Sponsored“Elon’s nightmare” could fund your retirementMarc Chaikin, the 60 year Wall Street veteran whose Chaikin Money Flow indicator sits on every Bloomberg termi...Chaikin Analytics | SponsoredYou’ve never seen anything like this beforeFor centuries, families like the Rothschilds, Morgans, and Rockefellers have quietly used one overlooked type ...Porter & Company | SponsoredBank of America: 'Digital Dollar Inevitable'Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...Decentralized Masters | SponsoredMy top 3 AI picks for the next decadeAlexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...The Oxford Club | SponsoredYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...Profits Run | SponsoredNVDA CEO says it’s a "once-in-a-generation opportunity"NVIDIA CEO Jensen Huang calls a little-known AI niche a once-in-a-generation opportunity, and it has nothing t...Monument Traders Alliance | SponsoredTrump goes "all-in" on Grand Canyon energy breakthroughA drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Fate Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Fate Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
